The fibrinolytic system contains an inactive proenzyme, plasminogen, which is converted to the active enzyme plasmin by two physiological plasminogen activators: tissue-type and urokinase-type plasminogen activators (t-PA and u-PA, respectively). Plasminogen activation mediated by t-PA is mainly involved in the dissolution of fibrin at the site of vascular injury, whereas u-PA binds to a specific cellular receptor (uPAR) and plays a role in pericellular proteolysis by activating cell-bound plasminogen. The fibrinolytic system is regulated at the level of plasminogen activators by specific inhibitors such as plasminogen activator inhibitor-1 (PAI-1), and at the level of plasmin by a 2 -antiplasmin.1) This system is implicated in several pathophysiological processes, including thrombosis, inflammation, vascular repair, tissue remodeling, tumor invasion, and angiogenesis.
2)While searching for a modulator of the fibrinolytic system, we identified several low-molecular-mass compounds that effectively enhance fibrinolytic activity.3) Malformin A 1 (Fig. 1A), a cyclic pentapeptide, is one of these compounds. 4) Malformin A 1 enhances the fibrinolytic activity of U937 human monocytoid cell line which can elaborate PA and PAI, 5) and which have been widely used to study the fibrinolytic system. The malformin effect is dependent on the existence of blood plasma, and its activity is abolished by a lysine analog that competes with plasminogen for the cell-surface receptor or fibrin, or by anti-u-PA serum. Thus, the plasminogen/u-PA system is involved in the action of malformin A 1 . However, malformin A 1 does not enhance fibrinolytic activity in cellfree systems. Therefore, malformin action requires both cellular and plasma-related functions. In this study, we attempted to elucidate the activities of plasma malformin cofactor and purified vitronectin after several activity-based fractionation steps. Malformin A 1 affects cytoskeletal reorganization, cell signaling, and the resultant cell-surface localization of plasminogen. This mechanism may account for the increase in the level of activation of cell-surface plasminogen.
MATERIALS AND METHODS
MaterialsMalformin A 1 was isolated from a culture of Aspergillus niger F7586 through ethyl acetate extraction, silica gel chromatography, and reverse-phase HPLC. Plasminogen was affinity purified from human plasma, 6) and the flowthrough fraction thus obtained was used as plasminogen-deficient plasma. The following materials were obtained from commercial sources: bovine vitronectin and bovine a 2 -macroglobulin from Yagai (Yagai, Yamagata, Japan); human fibrinogen, Arg-Gly-Asp (RGD) peptide, H-7, genistein, cytochalasin B, and nocodazole from Sigma-Aldrich (St. Louis, MO, U.S.A.); wortmannin and calphostin C from Kyowa Medex (Tokyo, Japan); LY294002, K252a, and PD98059 from Merck (Darmstadt, Germany); U-73122 from Wako (Osaka, Japan); Texas Red-X phalloidin from Invitrogen (Carlsbad, CA, U.S.A.); and t-butyloxycarbonyl-Val-LeuLys-4-methyl-coumaryl-7-amide (Boc-VLK-MCA) from Peptid...